Panzytrat capsule: Discontinuation

Discontinuation Active

Panzytrat capsule (pancreatic enzyme 25,000 U lipase, 22,500 U amylase, 1,250 U protease) is being discontinued. The supplier has advised us that stock of this product can no longer be secured from the manufacturer.

Who is affected?

Panzytrat capsules are indicated for patients with exocrine pancreatic enzyme deficiency, such as (but not restricted to): 

  • Cystic fibrosis
  • Chronic pancreatitis
  • Post-pancreatectomy
  • Post-gastrointestinal bypass surgery e.g. Billroth II gastroenterostomy
  • Ductal obstructions from neoplasm e.g. of the pancreas or common bile duct

Datasheet for panzytrat – Medsafe datasheet(external link)

When will Panzytrat be unavailable

Based on usual demand patterns, the available stock is expected to last until early 2023. It has an expiry date of 31 May 2023. We estimate that this will allow for about a 12-month period for patients to transition to other funded alternatives with the support of their treating clinician(s).

Alternative product

Pharmac currently funds a number of other pancreatic enzyme presentations. The clinical advice that we have received suggests that these other funded strengths of pancreatic enzymes can be used as alternatives to Panzytrat. Where appropriate, we encourage prescribers to discuss alternative options with their patients.

Schedule listings for pancreatic enzyme(external link)

Pancreatin monograph – NZ Formulary(external link)

Who to contact

If you take Panzytrat capsule, please talk to your pharmacist, doctor or the person who prescribed this medicine. They are best placed to discuss your individual clinical circumstances.

If you have any questions regarding this notification, please contact Pharmaco on 0800 80 4079 between 9.00 am - 5.00 pm, Monday to Friday or email at

If you have a question about funding for pancreatic enzymes, or any concerns regarding this discontinuation, please email